Arcutis Biotherapeutics, Inc. (ARQT)

NMS – Real Time Price. Currency in USD

26.19

-0.04 (-0.13%)

Market open: Aug 12, 2026, 3:53 PM EDT

26.07

-0.16 (-0.61%)

Previous after-hours: Aug 11, 2026, 7:58 PM EDT

07.08.2026

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 143,500 restricted stock units (RSUs) of Arcutis' common stock as well as options to purchase an aggregate of 37,000 shares of Arcutis' common stock to 24 newly hired employees.

06.08.2026

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

05.08.2026

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.13 per share a year ago.

05.08.2026

Arcutis Biotherapeutics Q2 Earnings Call Highlights

Arcutis Biotherapeutics NASDAQ: ARQT reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially, as demand for its ZORYVE topical treatments continued to rise across approved dermatology indications.

05.08.2026

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand growth Company raising 2026 full-year net product sales guidance to $525 million–$540 million Received approval to expand the indication for ZORYVE cream 0.3% for the topical treatment of plaque psoriasis to children down to the age of 2, the seventh FDA approval in four years FDA accepted sNDA for ZORYVE cream 0.05% to expand indication to include infants with mild to moderate atopic dermatitis aged 3 to 24 months and set target action date of February 23, 2027 Completed enrollment of the Phase 2 trial of ZORYVE foam 0.3% in individuals with vitiligo with disclosure of topline results and decision on program advancement anticipated in Q4 of 2026 Launched a virtual health platform and a partnership with a leading AI-enabled healthcare platform to help facilitate access to ZORYVE Maintained positive operating cash flow for the quarter WESTLAKE VILLAGE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended June 30, 2026, and provided a business update.

03.08.2026

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

Videos

No Data

There is no data to display

Press releases

07.08.2026

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05.08.2026

Arcutis Biotherapeutics, Inc. (ARQT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics Q2 Earnings Call Highlights

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Videos

No Data

Press releases

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics Q2 Earnings Call Highlights

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Videos

No Data

Press releases

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Search stocks

Arcutis Biotherapeutics, Inc. (ARQT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics Q2 Earnings Call Highlights

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Videos

No Data

Press releases

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics Q2 Earnings Call Highlights

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Videos

No Data

Press releases

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update